Goetz, Matthew P. http://orcid.org/0000-0002-4383-270X
Cicin, Irfan
Testa, Laura
Tolaney, Sara M. http://orcid.org/0000-0002-5940-8671
Huober, Jens
Guarneri, Valentina http://orcid.org/0000-0002-2375-8397
Johnston, Stephen R. D.
Martin, Miguel http://orcid.org/0000-0001-9237-3231
Rastogi, Priya
Harbeck, Nadia http://orcid.org/0000-0002-9744-7372
Shahir, Ashwin
Wei, Ran
André, Valérie
Rugo, Hope S. http://orcid.org/0000-0001-6710-4814
O’Shaughnessy, Joyce
Funding for this research was provided by:
Eli Lilly and company
Eli lilly and company
Eli Lilly and Company
Article History
Received: 28 November 2023
Accepted: 13 April 2024
First Online: 26 April 2024
Competing interests
: MPG reports financial Interests, Institutional, Advisory Board: ARC Therapeutics, Biotheranostics, Biotheryx, Blueprint Medicines, Novartis, Rna Diagnostics, Sanofi Genzyme; Financial Interests, Institutional, Other, Consulting: AstraZeneca, Seattle Genetics; Financial Interests, Institutional, Other, General Consulting: Lilly; Financial Interests, Personal, Invited Speaker, CME Activity: Research to Practice, Clinical Education Alliance, Medscape, MJH Life Sciences; Financial Interests, Personal, Invited Speaker, CME Panel Discussant: Total Health Conferencing; Financial Interests, Personal, Other, Moderator for CME Activity: Curio Science; Financial Interests, Institutional, Local PI: Lilly, Pfizer, LOXO, ATOSSA Therapeutics, AstraZeneca, Sermonix; travel support from Lilly. IC does not report any competing interests. LT is a speaker for Novartis, Roche, Pfizer, Zodiac, Lilly, Merck and Co., Daiichi-Sankyo, and Astra Zeneca. She is on the Advisory Boards for Eli Lilly and Company, Novartis, MSD, Amgen, Daiichi-Sankyo, AstraZeneca, and Pfizer. She receives educational support from Pfizer, Libbs Farmaceutica Ltd, United Medical, Lilly, Zodiac, Daichi-Sankyo, and Gilead. She receives grants from Novartis. She is also on the monarchE steering committee. SMT reports institutional research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, Gilead, NanoString Technologies, Seattle Genetics, and OncoPep; and consultant/advisory roles for Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, CytomX Therapeutics, Daiichi-Sankyo, Gilead, Ellipses Pharma, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Myovant, Zetagen, Umoja Biopharma, Artios Pharma, Menarini/Stemline, Aadi Biopharma, Bayer, Incyte Corp, and Jazz Pharmaceuticals. JH receives honoraria from Eli Lilly and Company, Novartis, Roche, Pfizer, AstraZeneca, Seagen, Gilead, amd Daiichi-Sankyo. She consults with Eli Lilly and company, Novartis, Roche, Pfizer, AstraZeneca, Gilead, and Daiichi-Sankyo. She reports travel expenses from Roche, Novartis, Daiichi-Sankyo, and Gilead. VG reports personal fees for advisory board membership for AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly and company, Exact Sciences, Gilead, Merck Serono, MSD, Novartis, Pfizer, Olema Oncology, Pierre Fabre; personal fees as an invited speaker for AstraZeneca, Daiichi Sankyo, Eli Lilly and company, Exact Sciences, Gilead, GSK, Novartis, Roche and Zentiva; personal fees for expert testimony for Eli Lilly. SRDJ reports grants or contracts from Pfizer, Puma Biotechnology, Eli Lilly, AstraZeneca, Novartis, and Roche–Genentech for research funding to institute for laboratory studies and clinical trials; consulting fees from Eli Lilly, AstraZeneca, Puma Biotechnology, Pfizer, Novartis, and Sanofi Genzyme for consulting or an advisory role; and payment or honoraria from Pfizer, Eisai, AstraZeneca, and Roche–Genentech for speaker’s bureau. MM has received research grants from Roche, PUMA and Novartis, consulting/advisory fees from AstraZeneca, Amgen, Taiho Oncology, Roche/Genentech, Novartis, PharmaMar, Eli Lilly, PUMA, Taiho Oncology, Daiichi Sankyo, Menarini/Stemline, and Pfizer and speakers’ honoraria from AstraZeneca, Lilly, Amgen, Roche/Genentech, Novartis, and Pfizer. PR does not report any competing interest. NH reports honoraria for lectures and/or consulting from Amgen, AstraZeneca, Daiichi-Sankyo, EPG Communication, Gilead, Lilly, MEDSCAPE, MSD, Novartis, Pierre-Fabre, Pfizer, Roche, Sandoz, Sanofi, Seagen; Springer, Viatris, Zuelligpharma. She reports a minority ownership Co-Director West German Study Group (WSG). AS, RW, and VA are employees of Eli Lilly and company and minor shareholders. HSR reports institutional research support from AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer; Sermonix Pharmaceuticals Inc.; and Stemline. She reports consultancy/advisory support from Puma, NAPO, Scorpion Therapeutics, Mylan, Daiichi Sankyo. JO discloses honoraria from AbbVie Inc, Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, Bayer, Bristol-Myers Squibb, Carrick Therapeutics, Celgene Corporation, Daiichi Sankyo, Eisai, G1 Therapeutics, GlaxoSmithKline, Genentech, Genzyme, Gilead Sciences, Immunomedics, Lilly, Merck, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Prime Oncology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Theralink, and Synthon.